Logo

SINT

Sintx Technologies, Inc.

SINT

Sintx Technologies, Inc. • NASDAQ
$4.15 ▲ 6.82% (+0.27)
Market Cap $11.45 M
52w High $7.36
52w Low $1.71
Dividend Yield 0%
P/E -1.11
Volume 116.86K
Outstanding Shares 2.76M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $208K ▲ $3.448M ▲ $-10.258M ▼ -4.932K% ▼ $-3.46 ▼ $-3.378M ▼
Q2-2025 $100K ▼ $2.671M ▲ $-2.318M ▼ -2.318K% ▼ $-0.91 ▲ $-2.151M ▼
Q1-2025 $369K ▼ $2.506M ▲ $-2.292M ▼ -621.138% ▼ $-1.29 ▼ $-2.089M ▼
Q4-2024 $542K ▲ $2.12M ▼ $-1.695M ▲ -312.731% ▲ $-1.26 ▲ $-1.456M ▲
Q3-2024 $367K $6.565M $-6.239M -1.7K% $-6.97 $-5.898M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.25M ▲ $11.364M ▲ $7.296M ▲ $4.068M ▲
Q2-2025 $4.32M ▼ $9.195M ▼ $5.207M ▼ $3.988M ▼
Q1-2025 $6.5M ▲ $11.449M ▲ $5.357M ▼ $6.092M ▲
Q4-2024 $3.598M ▼ $9.413M ▼ $5.519M ▼ $3.894M ▼
Q3-2024 $4.814M $11.303M $5.722M $5.581M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.539M ▼ $-2.517M ▼ $666K ▲ $3.781M ▲ $1.93M ▲ $-2.601M ▼
Q2-2025 $-2.318M ▼ $-2.409M ▼ $352K ▲ $-123K ▼ $-2.18M ▼ $-2.409M ▼
Q1-2025 $-2.292M ▼ $-1.301M ▼ $-63K ▼ $4.266M ▲ $2.902M ▲ $-1.364M ▼
Q4-2024 $-1.695M ▲ $-1.124M ▲ $10K ▲ $-102K ▼ $-1.216M ▼ $-1.27M ▲
Q3-2024 $-6.239M $-2.57M $-31K $2.858M $257K $-2.581M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Grant And Contract
Grant And Contract
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Sintx looks like a science and platform company that is still essentially pre‑revenue. Over the past several years, the statements show no meaningful sales and steady operating losses. The costs to run the business and pursue development have outweighed any early revenues, leading to recurring net losses each year. Reported loss per share looks very large, but that is heavily distorted by repeated reverse stock splits rather than a sudden collapse in the underlying business. Overall, this is a company still in the build‑out and validation phase, not yet in a mature commercial phase.

Balance Sheet

Balance Sheet The balance sheet is very small and quite lean. Assets, including cash, have trended down over time, and shareholder equity has been shrinking, showing that losses are gradually eroding the financial cushion. On the positive side, there is effectively no debt, so the company is not burdened by interest payments or large scheduled repayments. However, the absence of debt also suggests that Sintx has likely depended on issuing new shares to fund operations, which fits with the pattern of multiple large reverse splits. Financially, this is a thinly capitalized company that needs careful cash management and continued access to new funding.

Cash Flow

Cash Flow Cash flows reflect a business that consistently spends more cash than it brings in. Operating cash flow has been negative year after year, and free cash flow follows the same pattern since there is little to no capital spending. That means cash is steadily leaving the business to pay for research, staff, and overhead, while incoming cash from customers is still minimal. In absolute terms the burn rate appears modest, but relative to the small cash base it is important. The company’s ability to keep executing on its plans depends heavily on raising additional capital or signing agreements that bring in cash.

Competitive Edge

Competitive Edge Sintx occupies a narrow but potentially valuable niche in advanced ceramics, built around its silicon nitride technology. It holds a unique regulatory position as the only player with FDA clearance to use this material as a biomaterial, backed by a long clinical track record in spinal implants. A sizable patent portfolio, specialized manufacturing know‑how, and decades of focused experience reinforce this position and create barriers for new entrants. At the same time, Sintx is a tiny competitor in a medical device landscape dominated by much larger companies with deeper commercial, regulatory, and sales resources. Its bargaining power with partners, hospitals, and distributors is likely limited, and its success will depend on converting its scientific edge into strong commercial relationships.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of Sintx. The company has spent years building expertise around silicon nitride and has turned that into a broad pipeline: spinal implants, orthopedic and dental uses, coatings for metal implants, custom and 3D‑printed devices, infection‑resistant fabrics, and high‑performance industrial parts. The technology offers real differentiators such as bone‑friendly properties, resistance to infection, and good imaging characteristics. Management is also exploring hybrid materials and new manufacturing techniques, which could open additional markets. The main risk is execution: the R&D story is rich and technically impressive, but it must be narrowed, prioritized, and commercialized in a way that generates stable, repeatable revenue before financial constraints slow development.

Summary

Sintx is best viewed as an early‑stage, technology‑driven materials company in healthcare rather than a mature medical device business. Financially, it is still in a pre‑revenue or very low‑revenue phase, with recurring losses, a small and shrinking equity base, and ongoing negative cash flow. The lack of debt reduces financial pressure, but repeated reverse splits and a thin balance sheet highlight a reliance on external capital and a history of shareholder dilution. Strategically, the company’s strengths are its unique silicon nitride platform, regulatory clearances, patent portfolio, and long technical track record. These provide a defensible niche and the possibility of attractive applications in spine, orthopedics, dental, infection control, and select industrial markets. The key questions revolve around commercialization: how quickly and efficiently Sintx can convert this science into scaled products, partnerships, and recurring revenue streams, while managing its limited financial resources and competing against much larger medical device players.

NEWS

November 3, 2025 · 8:00 AM UTC

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System

Read more

October 20, 2025 · 7:00 AM UTC

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

Read more

October 14, 2025 · 7:00 AM UTC

SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics

Read more

September 8, 2025 · 7:54 AM UTC

SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds

Read more

September 8, 2025 · 7:00 AM UTC

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

Read more